^
Association details:
| Biomarker: | FLT3 F691L |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | dubermatinib (TP-0903) (AXL inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
TP-0903 is active in models of drug-resistant acute myeloid leukemia
Published date:
12/03/2020
Excerpt:
In vitro and in vivo, TP-0903 was active in multiple models of drug-resistant FLT3 mutant AML, including those involving the F691L gatekeeper mutation and bone marrow microenvironment–mediated factors.
DOI:
10.1172/jci.insight.140169
